High SLFN11 expression to predict sensitivity of FOLFOX regimen in stage 2-3 colon cancer patients with KRAS wildtype.

e14618 Background: Range of SLFN11 expression in colorectal cancer was observed, high SLFN11 expression might indicate sensitive to DNA Damage Agents (DDA). We aimed to investigate whether it predicts the sensitivity of oxaliplatin (one kind of DDA) in FOLFOX regimen. Methods: Tissue microarray(TMA) was made with 261 sporadic patients who received 5-FU based adjuvant chemotherapy. TMA was stained with anti-SLFN11 antibody (Abcam). The intensity and proportion was classified to 0-3, the final score was calculated by intensity plus proportion. The score higher than five was defined as strong expression. Results: There were 15.3% patients who showed high SLFN11 expression, 32.2% patients had KRAS mutation. SLFN11 was not correlated to stage, KRAS status and carcinoembryonic antigen (CEA). In all patients, SLFN11 was not related to overall survival (P=0.236, HR=2.12). However, in KRAS wildtype patients, all 23 high SLFN11 expression patients survived after 36 month follow up. They had significant better survi...